Although RSV is a frequent cause of acute respiratory infections (ARIs), an estimation of its incidence has proven challenging due to a lack of routine testing, overlapping clinical presentations with ...

As respiratory virus season approaches, doctors recommend that parents consult with pediatricians about new vaccination options to protect infants from RSV.

Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study published online in the August ...

AJMC®: Respiratory syncytial virus (RSV) infection is often considered a childhood disease. Could you speak to this common conception and to the observed prevalence of RSV infection in adults? WALSH: ...

"Although the primary purpose of nirsevimab is to prevent RSV-associated hospitalizations, this study demonstrates a clinically meaningful reduction in RSV-associated antibiotic use, revealing the ...

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing medically attended infections and hospitalizations. Maternal vaccination and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application ...